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Echinacea in infection 
Abstract 
Ongoing studies have developed strategies for identifying key bioactive compounds and chemical profiles 
in Echinacea with the goal of improving its human health benefits. Antiviral and 
antiinflammatory–antipain assays have targeted various classes of chemicals responsible for these 
activities. Analysis of polar fractions of E. purpurea extracts showed the presence of antiviral activity, with 
evidence suggesting that polyphenolic compounds other than the known HIV inhibitor, cichoric acid, may 
be involved. Antiinflammatory activity differed by species, with E. sanguinea having the greatest activity 
and E. angustifolia, E. pallida, and E. simulata having somewhat less. Fractionation and studies with pure 
compounds indicate that this activity is explained, at least in part, by the alkamide constituents. Ethanol 
extracts from Echinacea roots had potent activity as novel agonists of TRPV1, a mammalian pain 
receptor reported as an integrator of inflammatory pain and hyperalgesia and a prime therapeutic target 
for analgesic and antiinflammatory drugs. One fraction from E. purpurea ethanol extract was bioactive in 
this system. Interestingly, the antiinflammatory compounds identified to inhibit prostaglandin E2 
production differed from those involved in TRPV1 receptor activation. 
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ABSTRACT
Ongoing studies have developed strategies for identifying key bio-
active compounds and chemical profiles in Echinacea with the goal
of improving its human health benefits. Antiviral and antiinflamma-
tory–antipain assays have targeted various classes of chemicals re-
sponsible for these activities. Analysis of polar fractions of E. pur-
purea extracts showed the presence of antiviral activity, with
evidence suggesting that polyphenolic compounds other than the
known HIV inhibitor, cichoric acid, may be involved. Antiinflam-
matory activity differed by species, with E. sanguinea having the
greatest activity and E. angustifolia, E. pallida, and E. simulata
having somewhat less. Fractionation and studies with pure com-
pounds indicate that this activity is explained, at least in part, by the
alkamide constituents. Ethanol extracts from Echinacea roots had
potent activity as novel agonists of TRPV1, a mammalian pain
receptor reported as an integrator of inflammatory pain and hyper-
algesia and a prime therapeutic target for analgesic and antiinflam-
matory drugs. One fraction from E. purpurea ethanol extract was
bioactive in this system. Interestingly, the antiinflammatory com-
pounds identified to inhibit prostaglandin E2 production differed
from those involved in TRPV1 receptor activation. Am J Clin
Nutr 2008;87(suppl):488S–92S.
KEY WORDS Alkamide, antiinflammatory, antipain, antivi-
ral, cichoric acid, Echinacea, Echinacea angustifolia, Echinacea
pallida, Echinacea purpurea, Echinacea sanguinea, Echinacea
simulate, HIV, TRPV1 receptor
CENTER ORGANIZATION
The primary goal of the Iowa Center for Research on Botanical
Dietary Supplements is to improve our understanding of the
characteristics of Echinacea, Hypericum, and Prunella that con-
tribute to human health and thereby pave the way for optimizing
these supplements for study in future clinical trials. Our center
focuses on infection with an emphasis on antiviral, antiinflam-
matory, and antipain activities. This article summarizes some of
our work on Echinacea.
A central strategy of the Iowa center has been to use biological
diversity to help to identify active constituents and determine
mechanisms of action. It is tempting to consider the diversity of
these plant genera and the complexity of their constituents as
barriers to understanding their potential health benefits. How-
ever, the range of variation in these plants, when systematically
analyzed, provides a strong foundation on which to develop the
strategies and tools needed to produce the most efficacious prod-
ucts for a growing body of consumers.
The center is organized into 3 cores: Germplasm and Phyto-
chemical Profiling; Separations, Structure, Bioavailability; and
Administration, Data Management, Statistics, and Bioinformat-
ics. Three projects are supported: defining antiviral activities in
Echinacea, Hypericum, and Prunella species; antiinflammatory
activity of Echinacea, Hypericum, and Prunella species; and
pain-receptor-mediated antiinflammatory activity of Echinacea
and Hypericum species.
PRODUCTION OF WELL-CHARACTERIZED PLANT
MATERIAL
A unique resource of the center is our collection of a geneti-
cally diverse set of well-documented plant populations of Echi-
nacea and the conservation of these genetic stocks at the US
Department of Agriculture-Agricultural Research Service North
Central Regional Plant Introduction Station (NCRPIS). This re-
source gives us strength in controlling the production of plant
materials and links with our expertise in genomic analysis and
broad-based plant metabolic profiling and our ability to integrate
complex datasets by using bioinformatics and other statistical
tools. The NCRPIS, which is located at Iowa State University, is
one of the main active gene banks in the US National Plant
Germplasm System, and it conserves extensive collections of
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known-source medicinal plants, with an emphasis on Echinacea
and Hypericum.
Since the late 1990s, the NCRPIS has acquired150 distinct
wild populations (or accessions) of Echinacea, representing all
recognized species and varieties from throughout their ranges,
including 2 federally endangered taxa, E. laevigata and E. ten-
nesseensis. The genetic integrity of these populations is pre-
served by regenerating seed samples under controlled conditions
in screened field cages with insect pollinators, typically honey-
bees (1). To ensure unbiased sampling of Echinacea populations
for regeneration, research has been directed toward understand-
ing seed dormancy and methods to overcome it (2, 3).
During seed regeneration, taxonomic identities are verified
and populations are characterized for phenotypic traits with a
standardized descriptor list. Phenotypic descriptors along with
images and detailed passport data describing each accession are
available from the Germplasm Resources Information Network
database (4). Seeds of all available accessions are distributed for
research and educational purposes at no cost to the user.
Echinacea samples used by center researchers have typically
been produced from NCRPIS accessions. By using these acces-
sions produced under known conditions, we minimize both the
genetic and the environmental components of biochemical vari-
ation in the resulting products, which increases the overall re-
peatability of bioassays. Long-term, replicated field plantings of
the 3 primary medicinal species, E. angustifolia, E. pallida, and
E. purpurea, were established in 2003 to optimize root produc-
tion and determine the effects of disease and shading on plant
survival and productivity. Dried roots from these plantings have
been a major source of plant material for our research projects.
Additional accessions have also been supplied to researchers as
root samples from plants used for seed regeneration, after suc-
cessful completion of the seed-production process, and as leaf
and pollen samples. After production and processing, all plant
samples for center use are inventoried with a standardized coding
system, and unextracted dried plant materials are packaged in
nitrogen and stored frozen at20 °C. In addition to the supply of
plant materials for bioassays, a carefully selected, diverse array
of 40 Echinacea accessions is being characterized biochemi-
cally for alkamides and caffeic-acid derivatives and genetically
for both nuclear and chloroplast DNA variation. These charac-
terization data should be valuable for describing the extent of
chemical variation, elucidating taxonomic relations, and provid-
ing a framework for phylogenetic analysis and future bioassay.
ANTI-HIV ACTIVITIES OF ECHINACEA
The antiviral activities of Echinacea extracts and its metabolic
constituents are surprisingly poorly studied. A recent, prominent
study identifying a lack of efficacy of E. angustifolia extracts
against rhinovirus infection has discouraged additional clinical
antiviral studies on botanical extracts (5). However, recent in
vitro studies within our center identifying antiviral activities in
Echinacea against HIV are promising. Constituents responsible
for the anti-HIV activity in our plant extracts were identified
through bioactivity-driven fractionation studies. A example of
our success with this approach is shown here for E. purpurea.
Initially, extracts from 6 Echinacea species were tested for
inhibition of replication of the HIV molecular clone pNL4-3. All
HIV infectivity assays were performed in the HeLa37 cell line
that expresses the viral receptor and co-receptors (6). Known
titers of HIV were added to cells in the presence of the botanical
extract. Cells were fixed and immunostained for viral antigens at
40 h after infection. Cells immunopositive for HIV were repre-
sented as percentage of control values. Extracts from E. purpurea
consistently provided the most robust inhibition of HIV with
little or no cellular cytotoxicity. Increasing concentrations of E.
purpurea extract had antiviral activity with a 50% inhibitory
concentration (IC50) of 2.4 g/mL (Figure 1). This species
contains the anti-HIV compound cichoric acid and thus was
anticipated to inhibit HIV replication (7). To determine whether
constituents other than cichoric acid had antiviral activity, E.
purpurea extracts were fractionated. Seven fractions were gen-
erated; no fraction had detectable cytotoxicity or endotoxin con-
tamination (Figure 2A). Fraction 1, the most polar, had signif-
icant anti-HIV activity; the other fractions had no antiviral
activity. HPLC analysis of fraction 1 documented that a series of
caffeic acid derivatives and other polyphenolics including ci-
choric acid were present (Figure 2B). Subfractionation into 9
subfractions yielded 6 with anti-HIV activity (Figure 3); HPLC
analysis of these subfractions showed that each fraction was
composed of different constituents. Subfractions 1–6 all con-
tained numerous constituents including cichoric acid; subfrac-
tions 1–3, 1–4, 1–7, and 1–8 exhibited some antiviral activity
and contained multiple constituents that absorbed light at 330 nm
and likely are polyphenolics. Interestingly, subfraction 5 ab-
sorbed light at 254 nm but not at 330 nm and may contain
glycosylated flavanoids. We anticipate that we will successfully
continue to use this bioactivity-driven fractionation approach to
identify the botanical compounds responsible for the antiviral
activity.
ANTIINFLAMMATORY SCREENING USING RAW264.7
MACROPHAGES
The antiinflammatory activity of Echinacea extracts, frac-
tions, and constituents was assessed with RAW264.7 cells
treated with and without lipopolysaccharide, and prostaglandin
E2 (PGE2) accumulation was measured. This widely used screen
for antiinflammatory activity is based on PGE2 production aris-
ing from cyclooxygenase-1 and -2 activation, a key event in
inflammation. Initial studies showed that soxhlet ethanol extracts
of Echinacea provided the greatest antiinflammatory activity.
Activity of soxhlet extracts of E. purpurea, E. angustifolia, E.
pallida, E. tennesseensis, E. simulata, and E. sanguinea at 15
g/mL, which were harvested during the fall of 2003, 2004, and
2005, did not differ significantly by repeat extraction or harvest.
FIGURE 1. Ability of Echinacea purpurea ethanol extract (PI621307) to
inhibit HIV replication. Data shown represent the meanSEM for each data
point from 3 different experiments with triplicate samples in each experi-
ment.
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E. sanguinea inhibited PGE2 production to the greatest extent; E.
angustifolia, E. pallida, and E. simulata inhibited less; and E.
tennesseensis and E. purpurea extracts were not inhibitory at this
concentration (Figure 4) but were at higher concentrations (8).
Concentrations of alkamides and ketones in these extracts were
determined, but these compounds did not simplistically explain
bioactivity. For example, E. angustifolia and E. purpurea were
rich in Bauer Amide 8, which was not abundant in E. pallida.
There was relatively little cytotoxicity of Echinacea even at
doses 10-fold higher than those assayed for antiinflammatory
activity. All extracts reported here were negative for endotoxin
contamination.
HPLC fractions of E. pallida and E. angustifolia had similar
patterns of effects on PGE2 production, with the strongest inhi-
bition in fraction 3 for both species. Interestingly, the more polar
fractions (fractions 1 and 2 containing polyphenols such as caf-
feic acid and Bauer alkamides 1–7) had less antiinflammatory
activity at higher concentrations, but fraction 3, which contained
abundant alkamides (unique in this fraction for E. purpurea and
E. angustifolia were Bauer amides 8 and 9), significantly reduced
LPS-induced PGE2 production (Figure 5). Our observations are
consistent with observations of others showing antiinflammatory
activity with alkamide extracts containing Bauer alkamides 8 or
9 (9). However, because E. pallida does not contain amides 8 or
9; other compounds, possibly ketones, must contribute the ac-
tivity.
Numerous alkamides synthesized by our center were tested for
antiinflammatory activity, and all the synthesized alkamides (ie,
Bauer 2, 8, 10, 11, 13, and 14) screened to date significantly
inhibited the production of PGE2 (P 0.001) at 50 mol/L (8).
Only Bauer amide 14 significantly inhibited PGE2 production at
10 mol/L (P 0.05), although amides 8 and 12 at 10 mol/L
inhibited at P  0.08. From these data, amide 14 is the only
synthesized alkamide that significantly reduced PGE2 at all con-
centrations screened. These data suggest that the alkamides in
Echinacea are important for its antiinflammatory activity.
Amide 8 may play a key role because of its abundance in E.
angustifolia fraction 3, in which PGE2 production by LPS-
treated RAW264.7 cells was potently reduced (Figure 5).
Subfractionation of E. angustifolia fraction 3 showed that the
less polar subfractions have antiinflammatory activity, with sub-
fractions 3D and 3E exhibiting the greatest reduction in PGE2
accumulation (data not shown). Alkamides are present in sub-
fractions 3B-E: 3D contains alkamides 5, 8, 9, and 14; 3E con-
tains 10 and 11; 3B contains alkamide 1; and 3C contains alka-
mides 1, 2, 3, 5, 12, 13, and 14.
This series of studies suggests that Echinacea alkamides may
contribute to observed antiinflammatory activity because they
are readily identified in the active extracts and exhibit apprecia-
ble activity. However, results with purified alkamides indicate
that single compounds failed to completely account for antiin-
flammatory activity and, thus, may interact with each other or
with other compounds to explain the observed antiinflammatory
activity.
MEDIATION OF PAIN-RECEPTOR ACTIVITY BY
ECHINACEA
TRPV1 in pain and inflammation
TRPV1 (transient receptor potential channel, vanilloid sub-
family member 1, VR1) (10) is a ligand-gated cation channel pain
FIGURE 2. Inhibition of HIV infectivity by Echinacea purpurea fractions. (A) Ability of 7 HPLC-separated fractions (100g/mL) to inhibit HIV infection
(white bars) or cytotoxicity (black bars). Each bar represents the mean of triplicates. The antiviral activity found in fraction 1 that is highlighted with an asterisk
showed efficacy against HIV-1 as determined by a Student’s t test comparing the untreated and treated samples (P 0.0001). (B) HPLC analysis of E. purpurea
fraction 1. Phenolic acid standards were run to allow identification of compounds.
FIGURE 3. Antiviral activity and cytotoxicity associated with subfrac-
tions 1-9 from Echinacea purpurea fraction 1. All HIV infectivity (white
bars) and cytotoxicity (black bars) assays were performed with 100g/mL of
the fraction or subfraction. Values represent the mean SEM for 2 experi-
ments performed in triplicate. Asterisks represent findings that are signifi-
cantly different from control infections as determined by a Student’s t test (P
 0.0001).
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receptor. It was initially cloned by using capsaicin, the potent
compound of hot peppers, which is a strong ligand (11). TRP
channels are extremely nonselective; TRPV1 is activated by
factors including capsaicin, protons, noxious heat (42 °C), the
endocannabinoid anandamide, lipoxygenase product, and etha-
nol (12). It is considered to be a key integrator of external stimuli,
both chemical and physical, into the common signal of inward
ion currents (11). Receptors from the TRP channel family, as
well as other classes of receptors such as CB, ASIC, and Trek-1,
are predominantly expressed in sensory tissues, such as nocicep-
tors and skin. These receptors are thought to provide feedback to
sense, transmit, and integrate pain and associated inflammatory
responses (11). Growing evidence indicates that TRPV1 acts as
an integrator of inflammatory pain and hyperalgesia, making it
an excellent potential target for analgesic or antiinflammatory
agents. Because of its importance in pain and inflammatory re-
sponses, TRPV1 protein structure-activity relations are being
analyzed extensively to determine which TRPV1 sites are im-
portant for interaction with each of its ligands. TRPV1 is also
desensitized by its ligands. Desensitization of TRPV1 after its
activation in these neurons is crucial in blocking pain transmis-
sion (11). Therefore, compounds that serve as agonists have
potential use as analgesics or antiinflammatory agents. In addi-
tion, capsaicin can produce a hypotensive effect in spontane-
ously hypertensive rats, indicating that activation of TRPV1 may
contribute to the treatment of hypertension (13).
Echinacea species comparison
Because of reported effects on inflammatory pain, we inves-
tigated the effects of Echinacea extracts on TRPV1-dependent
inward ion currents by using transient expression of TRPV1 in
frog oocytes (11). In this system, TRPV1 cRNA is injected into
healthy oocytes and is expressed transiently; then the TRPV1-
expressing oocytes are bathed in Echinacea extracts or capsaicin
for 10 s. Whole-cell currents are recorded by a 2-electrode volt-
age clamp recording system. Extracts of roots of E. angustifolia
evoked a current 10-fold greater than a saturating dose of cap-
saicin (Figure 6). Echinacea extracts rapidly desensitize the
TRPV1 channel even in the absence of added calcium, which
suggests that TRPV1 activation may occur through a mechanism
different from that of capsaicin. Leaf and flower extracts also
activated TRPV1.
Identification of bioactive constituents
Aqueous extracts of Echinacea contain unusual polysaccha-
rides reported to be responsible for certain antiinflammatory
activities (14). When Echinacea is extracted with solvent con-
taining 90% water, polysaccharides are absent; thus, our eth-
anol extracts would presumably not contain them. To directly test
whether Echinacea polysaccharides activate the TVPR1 chan-
nel, we prepared water extracts of E. purpurea, E. angustifolia,
and E. pallida and tested them with the frog-oocyte model.
FIGURE 4. Extracts of Echinacea species from different harvest dates were studied at 15 g/mL for their effects on prostaglandin E2 (PGE2) production.
Data (originally ng/mL PGE2) were normalized to the DMSO-lipopolysaccharide (LPS)–treated control and are presented as means 95% CIs. E. angustifolia,
E. pallida, and E. sanguinea (P  0.001) reduced PGE2 production compared with medium  DMSO controls. Data shown are with LPS; studies were
conducted without LPS, but PGE2 values were not altered by Echinacea. *P 0.05 compared with mediumLPSDMSO in a Dunnett multiple-comparison
test. Redrawn from reference (8).
FIGURE 5. Preparative HPLC fractions of Echinacea angustifolia soxhlet ethanol extract were assessed for reduction of prostaglandin E2 (PGE2) production
and are presented as means  95% CIs. All treatments are shown with lipopolysaccharide (LPS) because the fractions did not alter PGE2 production in the
absence of LPS. Fractions 1 and 3 significantly reduced LPS-induced PGE2 production. n 3. **P 0.05, representative of a Dunnett multiple-comparison
test.
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Echinacea aqueous extracts did not activate TRPV1, which in-
dicates that the polysaccharides do not appear to be TRPV1
ligands. Because several bioactivities, including cannabinoid
CB pain-receptor activation (15) and antiinflammatory effects
(described here), can be attributed at least in part to the alkamide
constituents of Echinacea, we also tested the effect of 6 purified
Echinacea alkamides on TRPV1 with use of the frog oocyte
model. Interestingly, no alkamide tested activated the TRPV1
channel. We are now using a combination of subfractionation of
Echinacea extracts and bioassays to identify the bioactive con-
stituents. CB and TRP receptors appear to be intimately related.
CB1 stimulation modulates TRPV1 activities in cultured rat dor-
sal root ganglion cells, and CB1 and TRPV1 receptors are highly
coexpressed in nociceptive primary sensory neurons (15).
FUTURE OBJECTIVES
Our center’s overarching objectives include identifying com-
pounds contributing to the antiviral, antiinflammatory, and pain-
control effects of Echinacea and to Echinacea toxicity. We fur-
ther seek to assess the influence of plant species and population
on bioactive constituents and to understand their mechanisms of
action, in particular, the cellular signaling pathways and critical
receptors and the effects of their interactions. We will assess the
bioavailability of key constituents of Echinacea supplements to
fill this important gap, because bioavailability likely plays a key
role in translating the results of bioassays to potential human
health effects.
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